RBC Bioscience

RBC Bioscience Equity Ratio

The Equity Ratio of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 32.64 %. In the previous year, Equity Ratio was 31.93 % — a change of 2.20% (higher).

Equity Ratio

32.64 %

YoY

2.20%

Last updated:

Equity Ratio of RBC Bioscience is 2024 32.64 % . Equity Ratio of RBC Bioscience was 2023 31.93 % . It decreases by 2.20% higher compared to the previous year.

The RBC Bioscience Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
51.46 TWD
Jan 1, 2019
43.66 TWD
Jan 1, 2020
34.09 TWD
Jan 1, 2021
30.30 TWD
Jan 1, 2022
31.47 TWD
Jan 1, 2023
31.93 TWD
Jan 1, 2024
32.64 TWD
The RBC Bioscience Equity Ratio history
YEAREquity RatioYoY
32.64 %+2.20%
31.93 %+1.46%
31.47 %+3.87%
30.30 %-11.11%
34.09 %-21.92%
43.66 %-15.16%
51.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Equity Ratio of RBC Bioscience is 32.64 % in 2024.

Equity Ratio of RBC Bioscience changed from 31.93 % to 32.64 %, representing a 2.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RBC Bioscience

All Key Metrics — RBC Bioscience